N-Isopropylnoratropine
(Synonyms: 异丙托品杂质E,NINA) 目录号 : GC10378
An intermediate in the synthesis of ipratropium
Cas No.:22235-81-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
N-Isopropylnoratropine is a noratropine derivative and an intermediate in the production of ipratropium, an atropine-like bronchodilator drug via an anticholinergic pathway. N-Isopropylnoratropine is used to examine the stability of ipratropium [1].
Muscarinic acetylcholine receptors are acetylcholine receptors that form G protein-receptor complexes in the cell membranes of certain neurons and other cells.
N-Isopropylnoratropine is an intermediate in the production of ipratropium and used to examine the stability of ipratropium. Ipratropium exhibits broncholytic action by reducing the influence of cholinergic on the bronchial musculature. Ipratropium blocks muscarinic acetylcholine receptors and therefore promotes the degradation of cGMP. Ipratropium bromide (IB) is an anticholinergic bronchodilatory agent to treat chronic obstructive pulmonary disease. In anesthetized dogs, Ipratropium with 0.01 and 0.1 mg/ml constricted the airways to 22 +/- 2% and 20 +/- 3% of control, respectively, whereas larger concentrations caused bronchodilation [2]. In moderate asthmatic patients, Ipratropium bromide (IB) induced a significant shift of dose-response curve to inhalation of substance P (SP), suggesting that bronchoconstriction induced by SP could be attributed to a weak cholinergic activation [3].
References:
[1]. Kasawar GB, Farooqui M. Development and validation of a stability indicating RP-HPLC method for the simultaneous determination of related substances of albuterol sulfate and ipratropium bromide in nasal solution. J Pharm Biomed Anal. 2010 May 1;52(1):19-29.
[2]. Groeben H, Brown RH. Ipratropium decreases airway size in dogs by preferential M2 muscarinic receptor blockade in vivo. Anesthesiology. 1996 Oct;85(4):867-73.
[3]. Crimi N, Palermo F, Oliveri R, et al. Influence of antihistamine (astemizole) and anticholinergic drugs (ipratropium bromide) on bronchoconstriction induced by substance P. Ann Allergy. 1990 Aug;65(2):115-20.
| Cas No. | 22235-81-0 | SDF | |
| 别名 | 异丙托品杂质E,NINA | ||
| 化学名 | (3-endo)-8-(1-methylethyl)-8-azabicyclo[3.2.1]oct-3-yl ester α-(hydroxymethyl)-benzeneacetic acid | ||
| Canonical SMILES | O=C(C(CO)C1=CC=CC=C1)O[C@H]2C[C@H]3CC[C@H](N3C(C)C)C2 | ||
| 分子式 | C19H27NO3 | 分子量 | 317.4 |
| 溶解度 | ≤16mg/ml in ethanol;10mg/ml in DMSO;2mg/ml in dimethyl formamide | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.1506 mL | 15.753 mL | 31.506 mL |
| 5 mM | 0.6301 mL | 3.1506 mL | 6.3012 mL |
| 10 mM | 0.3151 mL | 1.5753 mL | 3.1506 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet